Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Short-term Outcomes of High Tibial Osteotomy Using a Plate Versus a Plate With an Interbody Fusion Cage in Adolescent Tibia Vara : a Comparative Study

NCT07400705 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-10-06
Last updated
2026-02-10

Condition(s) studied

Tibia Vara in Children

Investigational drug(s) / intervention(s)

high tibial osteotomy using interbody fusion cage

high tibial osteotomy using interbody fusion cage: correction of adolescent tibia vara with high tibial osteotomy using interbody fusion cage

Study summary

Tibia vara is a progressive angular deformity of the lower limb centered at the proximal tibial physis, producing a characteristic bowing of the leg. The condition is believed to result from an abnormal distribution of biomechanical stresses combined with an underlying genetic predisposition. (1) Excessive mechanical loading on the medial portion of the proximal tibial growth plate leads to asymmetric physeal activity, ultimately causing a pathologic varus deformity of the tibia.(²)

Eligibility

Sex
ALL
Min age
10 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Adolescents aged \[10-18\] years diagnosed with tibia vara. * Symptomatic varus deformity centered at the proximal tibia requiring surgical correction. * Both sexes included * Open or transitional growth plates are suitable for HTO. Exclusion Criteria: * Prior tibial realignment surgery on the same side. * Ages below 10 years or above 18 years * Active infection, progressive metabolic disorder (e.g., rickets) or skeletal dysplasia, neuromuscular disorder, or systemic inflammatory arthritis. * Complex deformities need external fixation as the first-line treatment. * Patients with chronic comorbidities. * Associated with fractures in the same limb

Primary outcome measure(s)

  • correction of tibia vara radiologically — 6 months
    Change in MPTA from baseline to 6 months, measured on radiographs by two blinded observers.
  • correction of tibia vara on radiographs — 6 months
    Change in MPTA from baseline to 6 months, measured on radiographs by two blinded observers.

Trial sites (1)

FacilityCityRegionStatus
Sohag Univesity Hospitals Sohag Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07400705 on ClinicalTrials.gov ↗ ← All trials in Egypt